Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

In his new role, Segerstrom will lead Acadia's global people and culture strategy, supporting the company's continued growth as it develops treatments for neurological and rare diseases with significant unmet medical needs.

Carl Segerstrom brings more than 25 years of experience in global human resources leadership in the biopharmaceutical industry, including 17 years at Merck. Most recently, he served as Senior Vice President of Human Resources for Merck's Human Health Division, supporting a global business with operations in 80 countries.

Read More:Ken Bertsch Joins Anteris Advisors as Senior Advisor

During his time at Merck, Segerstrom held several senior leadership positions, including Chief Talent Officer. In that role, he led the company's global talent strategy, executive succession planning, leadership development, and workforce transformation. Earlier in his career, he also held HR leadership roles at Pharmacia, Schering-Plough, and Pfizer across international markets.

Segerstrom has extensive experience in organizational transformation, talent strategy, and digital and AI-driven workforce initiatives. He has also led large-scale hiring programs, recruiting more than 10,000 employees each year, and managed workforce planning across global teams.

“Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “His experience driving transformation in complex, science-driven organizations will be instrumental as we continue to scale and advance our mission for patients.”

“I am excited to join Acadia at this important stage of growth,” said Mr. Segerstrom. “The companys focus on serving patients and advancing innovation is compelling, and I look forward to partnering with the leadership team to strengthen our culture, develop talent and support the company’s continued success.”

About Acadia Pharmaceuticals

Acadia develops treatments for neurological and rare diseases with the goal of improving the lives of patients with limited treatment options. Its portfolio includes the only FDA-approved therapies for Parkinson's disease psychosis and Rett syndrome. The company is also advancing a pipeline of new treatments, including late-stage programs for Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage therapies for other unmet medical needs.

Read More:Wiland Appoints Jacqueline Popelier as Chief Marketing Officer